ArticlePain reports2026
Stellate ganglion block causing reproducible improvement of allergic rhinitis and asthma: a case report.
Article in Pain reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stellate ganglion block (SGB) is hypothesized to influence immunologic and physiologic processes through autonomic modulation. Though similar effects of SGB on atopic disease have been intermittently observed over the past century, methodological concerns limit the internal and external validity of these prior efforts. Objectives: To describe a case of simultaneous and reproducible improvement in allergic rhinitis and asthma after SGB, and to contextualize this observation within the existing literature. Methods: A 35-year-old woman with Complex Regional Pain Syndrome (CRPS) following a radial head fracture underwent SGB as a part of routine CRPS management. Her incidentally-observed changes in allergic rhintis and asthma were assessed longitudinally using validated clinical outcome measures in a retrospective fashion. Results: The patient demonstrated improvement of her allergic rhinitis and asthma after SGB, exceeding MCID thresholds for meaningful clinical improvement of each condition. These benefits persisted for 9 months before a partial recurrence of her atopic airway disease. A second SGB was able to reproduce these improvements, again exceeding MCID thresholds for both allergic rhinitis and asthma. Conclusions: SGB's effects on atopic disease warrant reappraisal of SGB as a potential adjunct for atopic airway disease, particularly in light of recent experimental evidence suggesting that SGB may exert an immunomodulatory effect. This case therefore highlights a meaningful gap in the literature and underscores the need for systematic investigation of SGB as a potential adjunctive treatment for atopic airway disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.